Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.41 USD | +4.23% | +4.06% | -54.02% |
04-03 | Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating | MT |
04-02 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
Evolution of the average Target Price on Verve Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Verve Therapeutics, Inc.
Stifel Nicolaus | |
Guggenheim | |
Canaccord Genuity | |
Credit Suisse | |
Cantor Fitzgerald | |
Goldman Sachs | |
RBC Capital Markets | |
BMO Capital | |
JPMorgan Chase | |
Jefferies & Co. | |
William Blair & Co. |
EPS Revisions
- Stock Market
- Equities
- VERV Stock
- Consensus Verve Therapeutics, Inc.